Altimmune’s Next-Gen GLP-1 Curbs Heavy Drinking in Unequivocal Phase 2 alcohol use disorder win on July 28, 2026 Agonist Alcohol Use Disorder Altimmune drinking levels GLP-1/glucagon heavy drinking pemvidutide registrational Risk tolerability United States Food and Drug Administration Weight Loss World Health Organization +
Semaglutide Shows Promise in Reducing Alcohol Consumption, Small Study Reveals on February 13, 2025 addiction Alcohol Use Disorder Craving for alcohol Glucagon-Like Peptide 1 semaglutide Wegovy weight loss medication +